Minjee Lee1, M Mahmud Khan2. 1. Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, 915 Greene St, Suite 357, Columbia, SC, 29208, USA. 2. Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, 915 Greene St, Suite 357, Columbia, SC, 29208, USA. mkhan@mailbox.sc.edu.
Abstract
PURPOSE: It has been reported that cancer survivors are delaying or avoiding necessary care due to costs. Medication non-adherence is one of the important aspects of deferred treatment. This study estimates the prevalence of cost-related medication non-adherence (CRN) by gender and factors associated with CRN among cancer survivors. METHODS: Using 2006-2013 National Health Interview Survey (NHIS), we examined self-reported CRN among cancer survivors by gender. Descriptive statistics and multiple logistic regression models were used to examine gender differences in CRN. RESULTS: In a nationally representative sample of 15,159 cancer survivors, 7.4% of male and 12.5% of female reported CRN. Overall, the prevalence of CRN was found to be the highest for uninsured group and the lowest for Medicare, but gender differences persist for all insurance types, including Medicare. After controlling for relevant covariates, female cancer survivors were 27% more likely (odds ratio (OR) = 1.27, confidence intervals (CI), 1.06-1.53) than male to report CRN. With higher number of comorbidities and activity limitations, CRN rates tend to increase for both male and female cancer survivors. CONCLUSIONS: Significant gender differences in CRN were found among cancer survivors after controlling for differences in sociodemographic, health status, and insurance coverage. IMPLICATIONS FOR CANCER SURVIVORS: Given the rapid increase in prescription drug costs, it is important to monitor closely the CRN in high-risk subgroups.
PURPOSE: It has been reported that cancer survivors are delaying or avoiding necessary care due to costs. Medication non-adherence is one of the important aspects of deferred treatment. This study estimates the prevalence of cost-related medication non-adherence (CRN) by gender and factors associated with CRN among cancer survivors. METHODS: Using 2006-2013 National Health Interview Survey (NHIS), we examined self-reported CRN among cancer survivors by gender. Descriptive statistics and multiple logistic regression models were used to examine gender differences in CRN. RESULTS: In a nationally representative sample of 15,159 cancer survivors, 7.4% of male and 12.5% of female reported CRN. Overall, the prevalence of CRN was found to be the highest for uninsured group and the lowest for Medicare, but gender differences persist for all insurance types, including Medicare. After controlling for relevant covariates, female cancer survivors were 27% more likely (odds ratio (OR) = 1.27, confidence intervals (CI), 1.06-1.53) than male to report CRN. With higher number of comorbidities and activity limitations, CRN rates tend to increase for both male and female cancer survivors. CONCLUSIONS: Significant gender differences in CRN were found among cancer survivors after controlling for differences in sociodemographic, health status, and insurance coverage. IMPLICATIONS FOR CANCER SURVIVORS: Given the rapid increase in prescription drug costs, it is important to monitor closely the CRN in high-risk subgroups.
Entities:
Keywords:
Cancer survivorship; Cost; Gender disparity; Medication adherence
Authors: Kenneth M Langa; A Mark Fendrick; Michael E Chernew; Mohammed U Kabeto; Kerry L Paisley; James A Hayman Journal: Value Health Date: 2004 Mar-Apr Impact factor: 5.725
Authors: Deborah A Levine; Lewis B Morgenstern; Kenneth M Langa; John D Piette; Mary A M Rogers; Sudeep J Karve Journal: Ann Neurol Date: 2013-02-22 Impact factor: 10.422
Authors: Stella Chang; Stacey R Long; Lucie Kutikova; Lee Bowman; Denise Finley; William H Crown; Charles L Bennett Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: Dong Wook Shin; Jong Hyock Park; Jae Hyun Park; Eun Cheol Park; So Young Kim; Sung Gyeong Kim; Jin Young Choi Journal: Support Care Cancer Date: 2010-01-15 Impact factor: 3.603
Authors: Zhiyuan Zheng; Xuesong Han; Gery P Guy; Amy J Davidoff; Chunyu Li; Matthew P Banegas; Donatus U Ekwueme; K Robin Yabroff; Ahmedin Jemal Journal: Cancer Date: 2017-02-20 Impact factor: 6.860
Authors: Courtney P Williams; Amy Davidoff; Michael T Halpern; Michelle Mollica; Kathleen Castro; Benjamin Allaire; Janet S de Moor Journal: JCO Oncol Pract Date: 2022-08
Authors: Grace L Smith; Maria A Lopez-Olivo; Pragati G Advani; Matthew S Ning; Yimin Geng; Sharon H Giordano; Robert J Volk Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Riyad Kherallah; Mahmoud Al Rifai; Ishan Kamat; Chayakrit Krittanawong; Dhruv Mahtta; Michelle T Lee; Jing Liu; Khurram Nasir; Javier Valero-Elizondo; Jaideep Patel; Mouaz H Al-Mallah; Laura A Petersen; Salim S Virani Journal: Prev Med Date: 2021-07-07 Impact factor: 4.637